Skip to main content
Clinical Trials/NCT00595751
NCT00595751CompletedNot Applicable

Best Estimate Diagnosis Used to Evaluate EEG in Association With ADHD in a Multi-Site, Clinical Sample of Children and Adolescents

Lexicor Medical Technology, LLC10 sites in 1 country300 target enrollmentStarted: December 2007Last updated:
Conditions

Trial Snapshot

Phase
Not Applicable
Status
Completed
Sponsor
Enrollment
300
Locations
10
Primary Endpoint
'Best Estimate Diagnosis' of ADHD applied in the intended population in settings with the intended users

Study Overview

Brief Summary

The study will evaluate the effectiveness of a standardized EEG method with the intended clinical users in the intended clinical settings with the intended population (patients who would typically receive a clinician's evaluation for ADHD). Multiple sites will be examined to provide a sample of patients across numerous communities with different demographics. The goal is to evaluate if the predictive accuracy of EEG will not be inferior to that of a widely-used and extensively validated ADHD scale in the prediction of ADHD in the intended use population as evaluated by Best Estimate Diagnosis.

Study Design

Study Type
Observational
Observational Model
Cohort
Time Perspective
Prospective

Eligibility Criteria

Ages
6 Years to 18 Years (Child, Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Subject willing to voluntarily participate in a research study that includes EEG collection and analysis.
  • Family/patient seeking comprehensive clinical evaluation for attention and/or behavior concerns.
  • Male or female at least 6 years of age and who will not be over 17.99 years of age upon admission to study.
  • Willing to stop any and all current psychiatric medications prior to or by entry into study.
  • Subject and parent (or legal representative) of an educational level and degree of understanding sufficient to communicate suitably with the investigator, rater and study coordinator.

Exclusion Criteria

  • Previous diagnosis of mental retardation. IQ < 70 by previous records.
  • History of seizure disorder or of EEG abnormalities. On anticonvulsants for seizure control.
  • Metal plate or metal device in the head.
  • Suicide ideation or gesture and/or homicidal ideation or gesture.
  • Concomitant medications during participation in a research study. No prescription or nonprescription medications with psychoactive properties that may affect EEG (such as over-the-counter dietary supplements, pseudoephedrine, or phenylpropanolamine). No antipsychotics, no psychostimulants, no antidepressants. Washout of at least one week or longer depending on the medication and clinician's judgment. Medication used for medical reasons must be cleared by research staff with consideration of known effects on EEG.
  • Known serious medical problems (cardiovascular, hematological, liver, seizure disorder, renal, or chronic respiratory problems).

Outcomes

Primary Outcomes

'Best Estimate Diagnosis' of ADHD applied in the intended population in settings with the intended users

Time Frame: At prensentation to clinic with attention or behavior problems

Secondary Outcomes

No secondary outcomes reported

Investigators

Sponsor
Lexicor Medical Technology, LLC
Sponsor Class
Industry

Study Sites (10)

Loading locations...

Similar Trials

NeuroLex EEG-Based ADHD Assessment Aid,... | Clinical Trial